Mostafa Ronaghi - 02 Jan 2026 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Reporting relationship: Director
Issuer ticker: SMMT
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 18:44:55 UTC
Prior SEC filing: 06 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Bhaskar Anand, as Attorney-in-Fact for Mostafa Ronaghi

Key filing fact

Mostafa Ronaghi filed Form 4 for Summit Therapeutics Inc. (SMMT) on 06 Jan 2026.

Key facts

This page summarizes Mostafa Ronaghi's Form 4 filing for Summit Therapeutics Inc. (SMMT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 18:44.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001441876 Primary reporting owner

Ronaghi Mostafa

Relationship: Director
Address: C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI
Signature: /s/ Bhaskar Anand, as Attorney-in-Fact for Mostafa Ronaghi
Signature date: 06 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SMMT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +35,000
Change %
Price
Shares after: 35,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $17.52
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.

Footnote F2

Not applicable.